Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Renal cell carcinoma

P D Savage1

  • 1Section on Hematology/Oncology, Comprehensive Cancer Center of Wake Forest University, Bowman Gray School of Medicine, Winston-Salem, NC 27157-1082, USA.

Current Opinion in Oncology
|May 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaporation-induced foam stabilization in lubricating oils.

Proceedings of the National Academy of Sciences of the United States of America·2018
Same author

The safety and efficacy of early-initiation exercise training after acute venous thromboembolism: a randomized clinical trial.

Journal of thrombosis and haemostasis : JTH·2015
Same author

Development of a quantitative real-time PCR for the detection of Tenacibaculum maritimum and its application to field samples.

Journal of fish diseases·2012
Same author

The influence of obesity and consequent insulin resistance on coronary risk factors in medically treated patients with coronary disease.

International journal of obesity (2005)·2008
Same author

Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec.

Abdominal imaging·2004
Same author

Medical management of metastatic skeletal disease.

The Orthopedic clinics of North America·2000
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Renal cell carcinoma treatment is improving with low-dose biological response modifiers combined with chemotherapy. Advances in molecular biology aid in better patient selection and developing novel therapies for advanced kidney cancer.

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Renal cell carcinoma (RCC) presents significant clinical challenges, with limited curative treatment options for most patients.
  • High-dose biological response modifiers (BRMs) for RCC are associated with severe toxicity.
  • Emerging evidence supports the efficacy of lower-dose BRM regimens.

Purpose of the Study:

  • To review current challenges and advancements in treating renal cell carcinoma.
  • To explore the potential of modified dosing strategies for biological response modifiers.
  • To highlight the role of molecular biology in advancing RCC treatment.

Main Methods:

  • Review of current literature on renal cell carcinoma treatment strategies.
  • Analysis of data regarding biological response modifier efficacy and toxicity at different doses.

Related Experiment Videos

  • Discussion of advancements in molecular biology and their application to RCC.

    • Main Results:

    • Low-dose biological response modifier regimens, particularly in combination with chemotherapy, show promising results.
    • These lower-dose combinations may offer comparable or superior outcomes to high-dose monotherapy.
    • Molecular biologic techniques are improving patient classification and prognostic variable identification.

    Conclusions:

    • Optimized treatment strategies for renal cell carcinoma are emerging.
    • Lower-dose BRMs combined with chemotherapy represent a potentially safer and effective approach.
    • Molecular insights are paving the way for novel therapeutic agents and personalized medicine in RCC.